Company news

Dianthus Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)

June 27, 2024

Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)

June 11, 2024

Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 29, 2024

Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference

May 7, 2024

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 2, 2024

Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting

April 10, 2024

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results

March 20, 2024

Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

March 6, 2024

Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG)

February 25, 2024

Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement

May 2, 2023

Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan

March 30, 2023

Magenta Therapeutics to Explore Strategic Alternatives

February 1, 2023

Magenta Therapeutics Voluntarily Pauses the MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial to Investigate Drug Safety

January 24, 2023

Magenta Therapeutics Provides Update for MGTA-117 Phase 1/2 Dose Escalation Clinical Trial

December 19, 2022

Magenta Therapeutics to Host Conference Call and Webcast on Tuesday, December 13, 2022, to Review MGTA-117 Clinical Data from Ongoing Phase 1/2 Clinical Trial

December 11, 2022

Magenta Therapeutics Presents Positive MGTA-117 Clinical Data at the American Society of Hematology (ASH) Annual Meeting and Provides Program Updates

December 11, 2022

Magenta Therapeutics to Present Data at the 2022 American Society of Hematology (ASH) Annual Meeting

November 2, 2022

Magenta Therapeutics to Participate in the Credit Suisse 31st Annual Healthcare Conference

October 31, 2022

Magenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of Directors

August 16, 2022

Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights

August 3, 2022

Magenta Therapeutics to Participate in Panel Discussion at the 2022 Wedbush PacGrow Healthcare Conference

August 1, 2022

Magenta Therapeutics Reports First Quarter Financial Results, Early Clinical Observations from MGTA-117 Clinical Trial and Other Program Highlights

May 15, 2022

Magenta Therapeutics Focuses R&D and Operational Spending, Reduces Workforce and Extends Cash Runway

April 13, 2022

Magenta Therapeutics to Participate in Panel Discussion at the 42nd Annual Cowen Healthcare Conference

March 2, 2022

Magenta Therapeutics Highlights Recent Pipeline Progress and Milestone Expectations for 2022

January 9, 2022

Magenta Therapeutics to Present at the J.P. Morgan Healthcare Conference and the B. Riley Virtual Oncology Conference

January 4, 2022

Magenta Therapeutics Highlights Presentations of Data Related to Stem Cell Mobilization and Targeted Conditioning at the 2021 American Society of Hematology (ASH) Annual Meeting

December 13, 2021

Magenta Therapeutics Reports Third Quarter Financial Results and Program Highlights

November 3, 2021

Magenta Therapeutics Announces Data Presentations Related to its Mobilization and Conditioning Programs at the 2021 American Society of Hematology (ASH) Annual Meeting

November 3, 2021

Magenta Therapeutics Appoints Jeffrey Humphrey, M.D. as Chief Medical Officer

October 3, 2021

Magenta Therapeutics to Participate in 2021 Cantor Virtual Global Healthcare Conference

September 20, 2021

Magenta Therapeutics Announces IND Clearance for MGTA-117 Targeted Conditioning Clinical Trial

September 14, 2021

Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in August

August 2, 2021

Magenta Therapeutics Announces Update on U.S. FDA Investigational New Drug Application for MGTA-117 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

July 20, 2021

Magenta Therapeutics Appoints Caren Deardorf as Chief Commercial Officer

July 5, 2021

Magenta Therapeutics Appoints Thomas Beetham as Chief Legal Officer

June 13, 2021

Magenta Therapeutics Announces Additional Preliminary Positive Results from Ongoing Phase 2 Clinical Trial of MGTA-145 and Plerixafor in Patients with Multiple Myeloma at the American Society of Clinical Oncology (ASCO) Annual Meeting

June 3, 2021

Magenta Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

June 2, 2021

Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in May

May 13, 2021

Magenta Therapeutics Announces Positive Preliminary Results from Phase 2 Clinical Trial of MGTA-145 in Multiple Myeloma and Provides an Update on its Anticipated Clinical Study with MGTA-117

May 11, 2021

Magenta Therapeutics Announces $86.4 Million Common Stock Investment from Multiple Investors

May 11, 2021

Magenta Therapeutics Reports First Quarter Financial Results and Recent Program Highlights

May 5, 2021

Magenta Therapeutics Appoints David Nichols as Chief Technical Officer

April 18, 2021

Magenta Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease Conference

March 24, 2021

Magenta Therapeutics Presents Final Phase 1 Results of MGTA-145 Stem Cell Mobilization Clinical Trial and Preclinical Data from Targeted Conditioning Program at the European Society for Blood and Marrow Transplantation (EBMT) 2021 Annual Meeting

March 14, 2021

Magenta Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference

March 8, 2021

Magenta Therapeutics Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Program Highlights

March 2, 2021

Magenta Therapeutics to Present Additional Data from Phase 1 MGTA-145 Stem Cell Mobilization Program and Preclinical Updates on Targeting Conditioning Program at Transplantation and Cellular Therapy (TCT) 2021 Annual Meeting

February 7, 2021

Magenta Therapeutics Highlights Recent Progress and Expected Timing of 2021 Milestones, Including Four Ongoing and Planned Clinical Trials

January 10, 2021

Magenta Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

January 4, 2021

← Newer news releases · Older news releases →

Decks

The 5 newest of 18 decks. Every deck is listed under its year.